| Methods |
4‐week placebo washout; inclusion criteria= mean DBP >/= 100 mm Hg at end of washout period and mean DBP 100‐115 mm Hg 24 hours after capsule intake during placebo phase; 8‐week double‐blind treatment, titrated to response at 4 weeks |
| Participants |
Enalapril 5 mg: n=101(54 males,47 females); mean age=56.2(9.7) years; baseline SBP=163.2(16.4) mm Hg, DBP=99.5(6.1) mm Hg;
Spirapril 6 mg: n=101(50 males,50 females); mean age=58.0(7.9) years; baseline SBP=161.8(16.3) mm Hg, DBP=99.7(6.6) mm Hg;
Placebo: n=50(32 males,18 females); mean age=56.5(8.2) years; baseline SBP=161.3(18.2) mm Hg, DBP=98.2(6.9) mm Hg |
| Interventions |
Enalapril 5 mg once daily;
Spirapril 6 mg once daily;
Placebo |
| Outcomes |
Adjusted mean change from baseline in trough sitting DBP;
Adjusted mean change from baseline in peak sitting DBP |
| Notes |
Used week 4 BP data only; BP change reported, SD of change not reported, endpoint BP reported, endpoint SD not reported; imputed overall trial mean DBP SD of change; DBP data from Table 5, p. 455; BP measurement device not reported; Jadad score=2; funding source= Novartis |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
